Corvus Pharmaceuticals to present interim data on soquelitinib for atopic dermatitis at SID 2025 Annual Meeting.
Quiver AI Summary
Corvus Pharmaceuticals, Inc. announced that it will present interim data from its Phase 1 clinical trial of soquelitinib, a treatment for moderate to severe atopic dermatitis, at the Society for Investigative Dermatology 2025 Annual Meeting in San Diego from May 7-10, 2025. The presentation will include both an oral session and a poster, highlighting the drug's selective ITK inhibition mechanism. Additionally, the company plans to discuss this new data during its first quarter 2025 business update conference call and webcast on May 8, 2025. Corvus Pharmaceuticals focuses on ITK inhibition for immunotherapy in cancer and immune diseases, with soquelitinib as its lead product candidate.
Potential Positives
- Corvus Pharmaceuticals will present new interim data from its Phase 1 clinical trial for soquelitinib at the prestigious Society for Investigative Dermatology 2025 Annual Meeting, highlighting significant engagement with the scientific community.
- The presentation is scheduled for an oral session and a poster, offering a dual opportunity to share findings with key stakeholders in dermatology.
- The company will provide a business update alongside the trial data, which could positively influence investor sentiment and market perception during its first quarter 2025 conference call.
- Soquelitinib represents an innovative approach in treating moderate to severe atopic dermatitis, potentially positioning Corvus as a leader in this therapeutic area if the trial results are favorable.
Potential Negatives
- Announcement of interim data presentation may indicate that the clinical trial is still in early stages and results are not yet conclusive.
- Dependence on the upcoming conference call and webcast for financial results may create uncertainty for investors regarding current operations and financial health.
- Lack of detailed results or outcomes from the trial in the press release may affect investor confidence and market perception of the company's progress.
FAQ
What is the focus of the Phase 1 clinical trial for soquelitinib?
The trial evaluates the efficacy of soquelitinib in patients with moderate to severe atopic dermatitis.
When will the new data from the trial be presented?
The data will be presented at the Society for Investigative Dermatology 2025 Annual Meeting from May 7-10, 2025.
Who is presenting the data on soquelitinib?
Dr. Albert S. Chiou, Clinical Associate Professor at Stanford, will present the findings.
How can investors access Corvus Pharmaceuticals' conference call?
Investors can access the call by dialing 1-800-717-1738 or through the Corvus website.
What is Corvus Pharmaceuticals known for?
Corvus Pharmaceuticals specializes in developing ITK inhibition therapies for cancer and immune diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRVS Hedge Fund Activity
We have seen 53 institutional investors add shares of $CRVS stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 2,679,479 shares (+inf%) to their portfolio in Q4 2024, for an estimated $14,335,212
- POINT72 ASSET MANAGEMENT, L.P. removed 2,532,718 shares (-45.5%) from their portfolio in Q4 2024, for an estimated $13,550,041
- SAMLYN CAPITAL, LLC added 2,136,772 shares (+47.2%) to their portfolio in Q4 2024, for an estimated $11,431,730
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 1,000,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $5,350,000
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 796,121 shares (+363.6%) to their portfolio in Q4 2024, for an estimated $4,259,247
- VIVO CAPITAL, LLC added 737,298 shares (+49.2%) to their portfolio in Q4 2024, for an estimated $3,944,544
- SPHERA FUNDS MANAGEMENT LTD. added 500,491 shares (+inf%) to their portfolio in Q4 2024, for an estimated $2,677,626
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRVS Analyst Ratings
Wall Street analysts have issued reports on $CRVS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 03/26/2025
- H.C. Wainwright issued a "Buy" rating on 01/02/2025
- Jefferies issued a "Buy" rating on 11/13/2024
To track analyst ratings and price targets for $CRVS, check out Quiver Quantitative's $CRVS forecast page.
Full Release
Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting
Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting, which is taking place May 7-10, 2025 in San Diego, CA.
Presentation details are as follows:
Title:
Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action
Abstract #:
0437
Presenter:
Albert S. Chiou, M.D., MBA, Clinical Associate Professor, Dermatology and Director of Clinical Research in the Department of Dermatology at Stanford University Medical Center
Poster Presentation Date and Time:
May 8, 2025 from 4:30 – 6:00 pm PT
Oral Presentation Date and Time:
May 10, 2025 from 9:50 – 10:00 am PT
First Quarter 2025 Financial Results Conference Call and Webcast
Corvus will present details on the new data from the soquelitinib Phase 1 clinical trial during the Company’s first quarter 2025 business update conference call and webcast, which is scheduled for Thursday, May 8, 2025 at 4:30 pm ET / 1:30 pm PT. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on
this link
for instant telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the
investor relations
section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 60 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit
www.corvuspharma.com
or follow the Company on
LinkedIn
.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
[email protected]
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
[email protected]
